Bioengineered Artificial Skin Market, By Product Type (Bilayered Bioengineered Artificial Skin, Trilayered Bioengineered Artificial Skin, and Others), By Application (Chronic Wounds, Acute Wounds, and Others), By End User (Hospitals, Clinics, and Others), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Nov 2023

Code : CMI5697

Pages :165

Formats :

Excel and PDF

Industry : Biotechnology

Market News

Global Bioengineered Artificial Skin Market Recent Developments

New product launches

In June 2021, Stratatech Corporation, a subsidiary of Mallinckrodt Pharmaceuticals, launched the StrataGraft, a unique non-biologic, cellularized, bioengineered tissue designed to treat severe burns.
In March 2021, Avita Medical, U.S. based clinical and commercial company developing and marketing a range of respiratory and regenerative products, launched the Recell System in the U.S. The recell system is a spray-on skin substitute that uses a patient's own skin cells to treat acute burns.
In February 2021, TissueTech, privately-held biotechnology company launched the ABniox RT, a new aBniotic membrane product designed for use in wound healing and tissue repair.

Acquisition and partnerships

In June 2021, Smith & Nephew, Global medical device company announced the acquisition of Integra LifeSciences' global medical device manufacturing company’s Extremity Orthopedics business, which includes the development of bioengineered skin substitutes for wound care and tissue repair.
In March 2021, TissueTech announced a strategic partnership with Corneal Associates of New Jersey, U.S. to offer a new regenerative medicine solution for corneal injuries using bioengineered tissues.
In December 2020, Organogenesis Holdings Inc., leading regenerative medicine company, announced the acquisition of NuTech Medical, a company focused on developing innovative wound care products, including bioengineered skin substitutes.